Patents Examined by Aurora M Fontainhas
  • Method for the diagnosis of neuromyelitis optica
    Patent number: 10036746
    Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: July 31, 2018
    Assignee: PROTAGEN AG
    Inventors: Heike Göhler, Petra Rengers, Angelika Lüking, Stefan Müllner
  • Silk peptide for improving neuroprotective and neurofunctional effects and a method of its preparation
    Patent number: 10010574
    Abstract: A silk peptide having neuroprotective and neurofunctional activities and its preparation method are discussed. One method relates to preparing silk protein preferably having neuroprotective activity with weight average molecular weight of 200-100,000 by hydrolysis of silk fibroin; also discussed are a composition for preventing or treating brain disease comprising silk peptide and pharmaceutically acceptable carrier, and a composition for improving brain function.
    Type: Grant
    Filed: July 31, 2004
    Date of Patent: July 3, 2018
    Assignee: BRAINGUARD CO., LTD.
    Inventors: Sung Su Kim, Cheol Hyoung Park, Sang-Hyung Lee, Wan-Seok Joo, Won Bok Lee
  • Anti-alpha synuclein binding molecules
    Patent number: 9975947
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: May 22, 2018
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • Biomarkers for prediction, diagnosis, and monitoring of parkinson's disease
    Patent number: 9927445
    Abstract: A method for the risk detection, early diagnosis, prognosis, and monitoring of Parkinson's disease in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with Parkinson's disease, or an earlier sample from the individual of interest.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: March 27, 2018
    Inventors: Balwant Rai, Jasdeep Kaur
  • Binding agonist for treatment of neurological and other disorders
    Patent number: 9914781
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 13, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Tejinder Kaur Bhinder, Chong Ding, Xu Feng, Wenqing Jiang, Alan Peter Lewis, Yingli Ma, Guhan Nagappan, Radha Shah Parmar, Yangsheng Qiu, Liuqing Yang, Qing Zhang, Yanjiao Zhou
  • Anti-transthyretin antibodies
    Patent number: 9879080
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: July 2, 2016
    Date of Patent: January 30, 2018
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Humanized anti-tau(pS422) antibodies and methods of use
    Patent number: 9862763
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Human PAC1 antibodies
    Patent number: 9822178
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: November 21, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
    Patent number: 9822367
    Abstract: Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: November 21, 2017
    Assignee: RSEM, LIMITED PARTNERSHIP
    Inventor: Przemyslaw Sapieha
  • Direct conversion of cells to cells of other lineages
    Patent number: 9822338
    Abstract: Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 21, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Marius Wernig, Thomas C. Sudhof, Thomas Vierbuchen, Austin Ostermeier, Zhiping Pang
  • HSP20 inhibits amyloidogenesis and neurotoxicity
    Patent number: 9802991
    Abstract: The present inventions are compositions and methods of using at least a portion of an isolated and purified ?-crystallin polypeptide that includes one or more ?-pleated sheets and that prevents neurotoxicity and amyloidogenesis.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 31, 2017
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Allison Ficht, Theresa Good, Kenneth Carson, Sungmun Lee
  • Methods and compositions for the generation and use of conformation-specific antibodies
    Patent number: 9796784
    Abstract: The present invention features methods and compositions for the generation and use of conformation-specific antibodies or fragments thereof.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 24, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate
    Patent number: 9757398
    Abstract: The invention provides compositions and methods for treatment of Alzheimer's disease. Such methods entail administering agents that induce a beneficial immune and therapeutic response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain preferred embodiments of such methods, a preferred agent is amyloid beta peptide in combination with Sphingosine-1-phosphate, preferably delivered in certain embodiments in a liposomal formulation.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: September 12, 2017
    Assignee: EUROESPES BIOTECNNOLOGIA, S.L.
    Inventors: Carmen Vigo, Ramon Cacabelos
  • Anti-complement factor C1q antibodies and uses thereof
    Patent number: 9708394
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 18, 2017
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Human PAC1 antibodies
    Patent number: 9676851
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9670273
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: June 6, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Osteoprotegerin in neuroprotection
    Patent number: 9670288
    Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: June 6, 2017
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
  • Method for diagnosing alzheimer's disease (AD)
    Patent number: 9625459
    Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: April 18, 2017
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
  • Conformational-specific antibodies against A[?] oligomers
    Patent number: 9617332
    Abstract: The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric A? oligomers, wherein said antibody molecule does not bind human monomeric A? 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: April 11, 2017
    Assignee: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN
    Inventor: Thomas Bayer
  • Method, composition, isolation and identification of a plaque particle and related biomarker
    Patent number: 9618524
    Abstract: The disclosure relates to an in vitro technology of detecting presence of a plaque particle, isolating the plaque particle followed by its composition analysis in several diseases states or before the disease sets in. A mechanism and a process leading to plaque formation, identifying a component in the mechanism of plaque formation, an identification of a biomarker for diagnosis/early diagnosis of plaque associated disease is described. A method of screening a candidate agent as an anti-plaque agent using flow cytometer, mass spectrometer and specific biomarkers is performed. Provided also are kits for use in practicing embodiment of the methods. A plaqueproteome database is also generated with novel protein sequences for diagnosis and specific antibodies for specific proteins are also disclosed.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 11, 2017
    Assignee: Plaxgen Inc.
    Inventor: Shanmugavel Madasamy